Stock Track | Hua Medicine-B Soars 5.14% Intraday on Strong 2025 Earnings and Record Profitability

Stock Track

03/27

Hua Medicine-B's stock soared 5.14% during intraday trading on Friday, following the release of its impressive 2025 financial results.

The surge comes after the company announced a historic breakthrough into profitability, with an annual profit of RMB1.11 billion. Its core diabetes drug, dorzagliatin, saw sales volume jump 91% to over 4 million boxes, driving net sales up 93% to RMB 492.9 million. Gross profit surged 125% to RMB 280.4 million, with the margin improving significantly.

Investor sentiment was further buoyed by news of the drug's successful market expansion, including approval in Hong Kong, and the company's optimistic outlook for continued growth and pipeline development in the global diabetes treatment field.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1137662369"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137662369\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137662369?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137662369","market":"nz","top_or_hot":-1,"title":"Stock Track | Hua Medicine-B Soars 5.14% Intraday on Strong 2025 Earnings and Record Profitability","media":"Stock Track","content":"<p>Hua Medicine-B's stock soared 5.14% during intraday trading on Friday, following the release of its impressive 2025 financial results.</p><p>The surge comes after the company announced a historic breakthrough into profitability, with an annual profit of RMB1.11 billion. Its core diabetes drug, dorzagliatin, saw sales volume jump 91% to over 4 million boxes, driving net sales up 93% to RMB 492.9 million. Gross profit surged 125% to RMB 280.4 million, with the margin improving significantly.</p><p>Investor sentiment was further buoyed by news of the drug's successful market expansion, including approval in Hong Kong, and the company's optimistic outlook for continued growth and pipeline development in the global diabetes treatment field.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hua Medicine-B Soars 5.14% Intraday on Strong 2025 Earnings and Record Profitability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hua Medicine-B Soars 5.14% Intraday on Strong 2025 Earnings and Record Profitability\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-27 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hua Medicine-B's stock soared 5.14% during intraday trading on Friday, following the release of its impressive 2025 financial results.</p><p>The surge comes after the company announced a historic breakthrough into profitability, with an annual profit of RMB1.11 billion. Its core diabetes drug, dorzagliatin, saw sales volume jump 91% to over 4 million boxes, driving net sales up 93% to RMB 492.9 million. Gross profit surged 125% to RMB 280.4 million, with the margin improving significantly.</p><p>Investor sentiment was further buoyed by news of the drug's successful market expansion, including approval in Hong Kong, and the company's optimistic outlook for continued growth and pipeline development in the global diabetes treatment field.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02552","symbol_name":"华领医药-B","start_time":0,"source_url":"","article_id":"1137662369","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137662369","pubTimestamp":1774575455,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hua Medicine-B's stock soared 5.14% during intraday trading on Friday, following the release of its impressive 2025 financial results.The surge comes after the company announced a historic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02552":"华领医药-B"},"translate_title":"个股赛道|华领医药-B盘中大涨5.14%2025年盈利强劲盈利创纪录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02552":1},"content_text":"Hua Medicine-B's stock soared 5.14% during intraday trading on Friday, following the release of its impressive 2025 financial results.The surge comes after the company announced a historic breakthrough into profitability, with an annual profit of RMB1.11 billion. Its core diabetes drug, dorzagliatin, saw sales volume jump 91% to over 4 million boxes, driving net sales up 93% to RMB 492.9 million. Gross profit surged 125% to RMB 280.4 million, with the margin improving significantly.Investor sentiment was further buoyed by news of the drug's successful market expansion, including approval in Hong Kong, and the company's optimistic outlook for continued growth and pipeline development in the global diabetes treatment field.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}